EG-VEGF and Bv8: a novel family of tissue-restricted angiogenic factors

被引:58
作者
Ferrara, N [1 ]
LeCouter, J
Lin, R
Peale, F
机构
[1] Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA
[2] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2004年 / 1654卷 / 01期
关键词
EG-VEGF; VEGF-A; ovary; GPCR; endothelium; angiogenesis;
D O I
10.1016/j.bbcan.2003.07.001
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A novel family of angiogenic mitogens have been recently characterized. Endocrine gland-derived vascular endothelial growth factor (EG-VEGF), and the mammalian homologue of Bombina variegata peptide 8 (130), are two highly related endothelial cell mitogens and chemotactic factors with restricted expression profiles and selective endothelial cell activity. These peptides share two cognate G-protein coupled receptors. The expression of human EG-VEGF occurs predominantly in steroidogenic glands. Consistent with such an expression pattern, the human EG-VEGF gene promoter has a potential binding site for steroidogenic factor (SF)-1, a pivotal element for steroidogenic-specific transcription. In the human ovary, the expression of EG-VEGF is temporally and spatially complementary to the expression of VEGF-A, both in the follicular and in the luteal phase, suggesting complementary and coordinated roles of these molecules in ovarian angiogenesis. Also, EG-VEGF expression correlates with vascularity in the polycystic ovary syndrome, a leading cause of infertility. Bv8 expression is mainly restricted to the testis. The identification of these tissue-selective angiogenic factors raises the possibility that other secreted molecules with selectivity for the endothelium of other organs exist. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:69 / 78
页数:10
相关论文
共 82 条
[21]   Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene [J].
Ferrara, N ;
CarverMoore, K ;
Chen, H ;
Dowd, M ;
Lu, L ;
OShea, KS ;
PowellBraxton, L ;
Hillan, KJ ;
Moore, MW .
NATURE, 1996, 380 (6573) :439-442
[22]   Clinical applications of angiogenic growth factors and their inhibitors [J].
Ferrara, N ;
Alitalo, K .
NATURE MEDICINE, 1999, 5 (12) :1359-1364
[23]   ANGIOGENIC FACTORS [J].
FOLKMAN, J ;
KLAGSBRUN, M .
SCIENCE, 1987, 235 (4787) :442-447
[24]  
FOLKMAN J, 1992, J BIOL CHEM, V267, P10931
[25]   ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE [J].
FOLKMAN, J .
NATURE MEDICINE, 1995, 1 (01) :27-31
[26]   Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor [J].
Fraser, HM ;
Dickson, SE ;
Lunn, SF ;
Wulff, C ;
Morris, KD ;
Carroll, VA ;
Bicknell, R .
ENDOCRINOLOGY, 2000, 141 (03) :995-1000
[27]   Angiogenesis and its control in the female reproductive system [J].
Fraser, HM ;
Lunn, SF .
BRITISH MEDICAL BULLETIN, 2000, 56 (03) :787-797
[28]   A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio [J].
Fulghesu, AM ;
Ciampelli, M ;
Belosi, C ;
Apa, R ;
Pavone, V ;
Lanzone, A .
FERTILITY AND STERILITY, 2001, 76 (02) :326-331
[29]  
Garner Alec, 1994, P1625
[30]   The role of VEGF in normal and neoplastic hematopoiesis [J].
Gerber, HP ;
Ferrara, N .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2003, 81 (01) :20-31